Abstract
Annual screening for lung cancer by low-dose computed tomography (LDCT) reduces mortality. Despite no cost-share for covered individuals, limited availability and frequent ‘false alarm’ findings have impeded widespread adoption, diminishing potential population health gains. We examined a model of the clinical and economic effects of introducing an accessible blood-based genomic test (BGT) used as a pre-screen to support more rapid and refined uptake of LDCT screening within the US Medicare population.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
